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Abstract
Background: In vitro bioassays are important in the evaluation of plants with possible hepatoprotective effects. The
aims of this study were to evaluate the pretreatment of HepG2 cells with hepatoprotective agents against the damage
induced by carbon tetrachloride (CCl4) and paracetamol (APAP).
Methods: Antioxidative activity was measured using an assay to measure 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical
scavenging. The in vitro hepatotoxicity of CCl4 and APAP, and the cytotoxic and hepatoprotective properties of silymarin
(SLM), silybinin (SLB), and silyphos (SLP) were evaluated by measuring cell viability; activities of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH); total antioxidant capacity (TAOxC); and reduced
glutathione (GSH), superoxide dismutase (SOD), and lipid peroxidation (malondialdehyde (MDA) levels).
Results: Only SLB and SLM showed strong antioxidative activity in the DPPH assay (39.71 ± 0.85 μg/mL and 14.14 ± 0.
65 μg/mL, respectively). CCl4 induced time- and concentration-dependent changes. CCl4 had significant effects on cell
viability, enzyme activities, lipid peroxidation, TAOxC, and SOD and GSH levels. These differences remained significant up
to an exposure time of 3 h. APAP induced a variety of dose- and time-dependent responses up to 72 h of exposure. SLM,
SLB, and SLP were not cytotoxic. Only SLB at a concentration of 100 μg/mL or 150 μg/mL significantly decreased the
enzyme activities and MDA level, and prevented depletion of total antioxidants compared with CCl4.
Conclusions: CCl4 was more consistent than APAP in inducing cell injury. Only SLB provided hepatoprotection. AST, LDH,
and MDA levels were good markers of liver damage.
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Background
Medicinal plants with hepatoprotective activity contain a
large number of bioactive molecules. The identification of
these molecules contained in a biomass complex requires
careful selection and execution of appropriate bioassays
during the various stages of the research process [1]. In
vitro bioassays are important in the evaluation of plants
with possible hepatoprotective effects.
Human hepatoma cell lines have been proposed as an
alternative to human hepatocytes for in vitro models of
normal liver cells. The potential advantages of hepatoma
cells are that, as an immortalized cell line, they are readily
available in large quantities, they are easy to maintain
because they can be cryopreserved, and their drug-
metabolizing enzyme activities do not decrease in cultiva-
tion, as happens in primary cultures of human hepatocytes
[2]. However, an obvious disadvantage is that the mecha-
nisms underlying drug metabolism and toxicity may be
abnormal in transformed cells. Despite these issues, the
HepG2 hepatoma cell line is used widely in studies of liver
function, metabolism, and drug toxicity [3, 4]. HepG2 cells
also possess many of the biochemical and morphological
characteristics of normal hepatocytes [5]. Because they
retain many characteristics of normal liver cells, these cells
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are used in studies to determine whether medicinal plants
have hepatoprotective activities [6, 7].
One hepatoprotective agent used widely in the treatment
of various liver disorders, such as hepatitis or fatty infiltra-
tion caused by alcohol or toxins, is the standardized extract
of Silybum marianum, known as milk thistle or silymarin
(SLM) [8–11]. It is a complex mixture of the flavonolignans
silybinin (SLB), silychristin, silydianin, and isosilybin.
SLB, a polyphenolic molecule, is the major component
of SLM and is responsible for its pharmacological activ-
ity [12, 13]. SLM is poorly absorbed, although the
bioavailability of SLB is higher than that of phosphat-
idylcholine (silyphos (SLP)) [14, 15].
The major inducers of hepatic damage used when
evaluating hepatoprotective activity are paracetamol
(acetaminophen, APAP) and carbon tetrachloride (CCl4).
However, there are few reports on their use and in vitro
characteristics [6, 7, 16]. The mechanisms responsible
for the in vivo liver toxicity of both compounds are
complex and involve several cell types [17, 18]. CCl4
undergoes metabolic activation in a cytochrome P-450-
dependent step to produce free radicals, which can initi-
ate lipid peroxidation. The toxicity induced by CCl4 in
vivo and in cultured hepatocytes involves stimulation of
lipid peroxidation, which is detected as an increase in
malondialdehyde (MDA) formation [19]. APAP is metabo-
lized mainly in the liver to excretable glucuronide and sul-
fate conjugates. However, the hepatotoxicity of APAP has
been attributed to the formation of toxic metabolites,
which occurs when APAP is activated by hepatic cyto-
chrome P-450 [20] to a highly reactive metabolite N-
acetyl-P-benzoquinoneimine (NAPQI) [21]. NAPQI is
initially detoxified by conjugation with reduced gluta-
thione (GSH) to form mercapturic acid. However,
when its rate of formation exceeds the rate of detoxifi-
cation by GSH, NAPQI oxidizes tissue macromolecules
such as lipids and —SH group proteins, and calcium
homeostasis is altered by depletion of GSH [22].
The aims of this study were to evaluate the hepatopro-
tective activities of SLM, SLB, and SLP against liver dam-
age induced by APAP and CCl4 in the HepG2 cell line.
Methods
General
SLB, SLM, 2,2-diphenyl-1-picrylhydrazyl free radical
(DPPH), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetra-
zolium bromide (MTT), and CCl4 (99.9%) were purchased
from Sigma-Aldrich Chemical Co. (St Louis, MO, USA).
SLP was purchased from Medix, S.A. de C.V. (México City,
D.F. México), and dimethyl sulfoxide (DMSO) was pur-
chased from ACS Research Organics (Cleveland, OH,
USA). Total antioxidant capacity (TAOxC), GSH, super-
oxide dismutase (SOD), and thiobarbituric acid reactive
substances were purchased from Kit OXItek (Buffalo, NY,
USA). Dulbecco’s modified Eagle’s medium advanced
(DMEMA) with and without phenol red, fetal bovine
serum, trypsin 0.25% (1×), penicillin G (100 IU/mL),
streptomycin (100 μg/mL), and phosphate-buffered saline
(PBS) were purchased from Gibco Invitrogen (Carlsbad,
CA, United States). Aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), and lactate dehydrogenase
(LDH) activities were measured using an ILab 300 Plus
chemistry analyzer (Instrumentation Laboratory, Bedford,
MA, USA).
Measurement of free radical reduction using the DPPH assay
Antioxidant activity was measured as described previ-
ously by Salazar et al. [23]. Briefly, the hepatoprotective
agents were dissolved in ethanol to obtain stock solu-
tions (1000 μg/mL), from which serial dilutions were
made. Diluted solutions (0.5 mL of each) were mixed
with 0.5 mL of 125 μM DPPH and allowed to react for
30 min. Ultraviolet absorbance was recorded at 517 nm
(Multiskan EX; Thermo/LabSystems, Vantaa, Finland).
The experiment was performed in triplicate and the
average absorption was recorded for each concentration.
The same procedure was followed for the quercetina
(positive control).
Cell culture
HepG2 human liver hepatoma cells were obtained from the
Laboratory of Liver, Pancreas and Motility, Department of
Experimental Medicine, Faculty of Medicine, Universidad
Nacional Autónoma de México, México City, DF, México.
Cells were grown in standard conditions: supplemented
DMEMA at 37 °C in a humidified 5% carbon dioxide at-
mosphere. When the cells reached 80–90% confluence,
they were trypsinized and plated at 30,000 cells per well in
a 96-well microplate, 1 × 106 cells per well in six plates, or
5 × 107 cells per well in a single dish, depending on the de-
termination. The cells were used after attachment.
CCl4-induced toxicity in HepG2 cells
HepG2 cells were incubated in medium or treated with
the toxic agent (20 mM, 30 mM, or 40 mM CCl4 in
0.05% DMSO) for 1, 1.5, 2, or 3 h. The evaluation assays
were performed using standard methods as described in
the “Evaluation assays” section below.
APAP-induced toxicity in HepG2 cells
HepG2 cells were treated with the toxic agent (2 mM,
4 mM, or 8 mM APAP) or incubated with medium only
for 12, 24, 48, or 72 h. The evaluation assays were per-
formed using standard methods as described in the
“Evaluation assays” section below.
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Effects of SLM, SLB, and SLP on HepG2 cells
The cytotoxic effects of SLM, SLB, and SLP were mea-
sured in HepG2 cells exposed for 12 h to compounds at
10, 100, or 150 μg/mL in supplemented DMEMA.
HepG2 cells in medium only were used as a negative
control. The evaluation assays were performed using
standard methods as described in the “Evaluation assays”
section below.
In vitro assay to identify hepatoprotective effects
The hepatoprotective effects of SLM, SLB, and SLP on
HepG2 cells were measured as follows. Normal control
cells were incubated with DMEMA in DMSO (0.05% v/v)
for 12 h. For toxic treatment, cells were incubated with
DMEMA in DMSO (0.05% v/v) for 12 h and then treated
with DMEMA with 40 mM CCl4 for 1.5 h. For SLM treat-
ment, cells were incubated with DMEMA with SLM at 10,
100, or 150 μg/mL for 12 h and then treated with 40 mM
CCl4 for 1.5 h. For SLB treatment, cells were incubated
with DMEMA with SLB at 10, 100, or 150 μg/mL for 12 h
and then treated with 40 mM CCl4 for 1.5 h. For SLP
treatment, cells were incubated with DMEMA with SLP
at 10, 100, or 150 μg/mL for 12 h and then treated with
40 mM CCl4 for 1.5 h. The evaluation assays were
performed using standard methods as described in the
“Evaluation assays” section below.
Evaluation assays
Each assay was performed in triplicate and the experiments
were repeated three times.
Cell viability assay
Cell viability was assessed using the MTT reduction assay
with slight modifications [24]. This colorimetric assay
involves the conversion of MTT to a purple formazan de-
rivative by mitochondrial succinate dehydrogenase, which
is present only in viable cells. The cells were treated with
SLM, SLB, SLP, and/or the toxic agent. The medium was
then removed and the cells were then incubated with
MTT (0.5 mg/mL) for 2 h, after which the formazan crys-
tals were dissolved with 200 μL/well of DMSO. Absorb-
ance was measured at 570 nm (Multiskan EX; Thermo/
LabSystems, Vantaa, Finland). Viability was defined as the
ratio of the absorbance of treated cells to that of untreated
control cells and is expressed as a percentage.
Measurement of AST, ALT, and LDH activities
AST, ALT, and LDH activities were measured using an
ILab 300 Plus system and Instrumentation Laboratory
assay kits. HepG2 cells were treated with SLM, SLB, SLP,
and/or the toxic agent. The supernatant was removed
from the wells, and the enzyme activities were measured
immediately. The results are expressed as IU/L.
Measurement of TAOxC
TAOxC was measured in lysed HepG2 cells using an
Antioxidant Assay kit from Cayman Chemical Company
(Ann Arbor, MI, USA). The kit is based on the ability of
antioxidants in the sample to inhibit the oxidation of
2,2’-azino-bis-3-ethylbenzothiazoline (ABTS) to ABTS+
by metmyoglobin. HepG2 cells were treated with SLM,
SLB, SLP, and/or the toxic agent. After treatment, the
adherent cells were scraped off and suspended in 5 mM
potassium phosphate, pH 7.4, containing 0.9% sodium
chloride and 0.1% glucose, sonicated, and placed on ice.
The supernatant of the lysed cells was used to measure
TAOxC. Absorbance in the well was measured after
5 min at a wavelength of 405 nm on a microplate reader
(Multiskan EX; Thermo/LabSystems, Vantaa, Finland).
The results are expressed as millimoles of antioxidant.
Measurement of GSH level
GSH level was quantified using a Glutathione Assay kit
from Cayman Chemical Company. The assay kit is based
on the enzymatic 5,5’-dithiobis-2-(nitrobenzoic acid)
(DTNB) disulfide dimer-oxidized GSH reductase recyc-
ling method. After treatment, the medium was removed
from the wells, and the adherent cells were scraped off
and suspended in 0.5 mL of 50 mM phosphate, pH 6.5,
containing 1 mM ethylenediaminetetraacetic acid, soni-
cated, and placed on ice. The supernatant of lysed cells
was used to measure GSH level. Absorbance of the yel-
low product in the well was measured at a wavelength of
405 nm on a microplate reader at 5 min intervals for
30 min. The total GSH activity was measured using the
kinetic method from a standard curve of GSH. The re-
sults are expressed as micromoles of GSH per liter.
Measurement of SOD activity
SOD activity was measured using a Superoxide Dismutase
Assay kit from Cayman Chemical Company, which uses a
colorimetric assay to measure the concentration of forma-
zan crystals. This assay uses a tetrazolium salt for the detec-
tion of superoxide radicals generated by xanthine oxidase
and hypoxanthine. After treatment, the medium was re-
moved from the wells, the adherent cells were scraped off
and suspended in 20 mM HEPES buffer, pH 7.2, containing
1 mM EGTA, 210 mM mannitol, and 70 mM sucrose),
sonicated, and placed on ice. To measure SOD activity, the
diluted radical detector and the supernatant of lysed cells
or standard were added to each well of a 96-well plate, and
xanthine oxidase was added. Absorbance in the well was
measured at a wavelength of 460 nm after 20 min on a
microplate reader. The results are expressed as IU/mL.
Measurement of lipid peroxidation
The concentration of MDA, the end product of lipid
peroxidation, was measured using a thiobarbituric acid
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reactive substance (TBARS) Assay kit from Cayman
Chemical Company. After treatment, the medium was
removed from the wells, adherent cells were scraped off,
suspended in cold PBS, sonicated, and placed on ice.
The supernatant from lysed cells or standard, sodium
dodecyl sulfate, and the color reagent were added to
each vial. The vial was heated at 100 °C for 1 h and then
immediately cooled in an ice bath and centrifuged. The
content of each vial was transferred to a well in a micro-
plate. The absorbance of the product was measured at a
wavelength of 540 nm on a microplate reader. The
extent of lipid peroxidation was quantified by estimating
the MDA concentration. The results are expressed as
micromoles of MDA equivalents formed per liter.
Statistical analysis
The half-maximal inhibitory concentration (IC50) values
were calculated by regression analysis. The results are
expressed as mean ± standard deviation (SD). The data
were analyzed using one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple-comparison
test using Prism software (v. 6.0; GraphPad, San Diego,
CA, USA). Differences between means were considered
significant at P <0.05.
Results
DPPH radical-scavenging activity
The DPPH radical-scavenging activity of SLM, SLB, and
SLP was evaluated. The IC50 values were 39.71 ±
0.85 μg/mL, 14.14 ± 0.65 μg/mL, and 169.53 ± 2.19 μg/
mL, respectively. Quercetin (used as a positive reference)
scavenged DPPH radicals completely, and its IC50 value
was 2 μg/mL.
CCl4-induced toxicity in HepG2 cells
The toxic effects of CCl4 were time and concentration
dependent (Fig. 1). Compared with the vehicle control,
there were significant differences in cell viability; AST,
ALT, and LDH activities; lipid peroxidation; TAOxC;
and SOD and GSH levels. These differences remained
significant up to an exposure time of 3 h (P <0.01).
APAP-induced toxicity in HepG2 cells
The toxic effects of APAP are shown in Fig. 2. The release
of AST, ALT, and LDH increased during the first 12 h in
HepG2 cells exposed to APAP, after which it declined; at
72 h, the effect was not related to time or concentra-
tion. TAOxC and SOD and GSH concentrations, and
cell viability decreased and MDA concentration in-
creased in a dose- and time-dependent manner. These
changes remained significant up to an exposure time of
72 h (P <0.01).
Effects of SLM, SLB, and SLP in HepG2 cells
The cytotoxic effects of SLM, SLB, and SLP on HepG2 cells
exposed for 12 h are shown in Fig. 3. The compounds were
considered to be toxic if there was a >60% decrease in cell
viability compared with untreated cells, an AST level
>50 IU/L, ALT level >30 IU/L, TAOxC >2 mM, or an
MDA, SOD, or GSH concentration greater than that of the
control (criteria established previously) [25]. According to
these definitions, the compounds were not considered cyto-
toxic and were used to evaluate hepatoprotective activity.
In vitro hepatoprotective effects
The hepatoprotective effects of SLM, SLB, and SLP on
HepG2 cells are shown in Fig. 4. HepG2 cells were pre-
treated with a hepatoprotective agent and subsequently
exposed to CCl4 to induce damage. Only SLB at a con-
centration of 100 μg/mL or 150 μg/mL significantly
decreased the levels of AST, LDH, and MDA, and pre-
vented depletion of TAOxC compared with CCl4 (P
<0.01). Pretreatment with SLM at 10 or 100 μg/mL and
SLP at any concentration did not prevent the reduction
in TAOxC compared with CCl4. Pretreatment with SLM
only at 150 μg/mL reduced the enzyme levels compared
with CCl4 (P <0.01).
Discussion
In this study, we used the HepG2 cell line to evaluate
the hepatoprotective activity of SLM, SLB, and SLP
against liver damage induced by APAP and CCl4 in an
attempt to establish a simple strategy for monitoring the
hepatoprotective activities of plant extracts without
high-end and excessive testing.
Cells exposed to these toxic agents lose cell viability,
release liver enzymes into the culture medium, do not
metabolize the tetrazolium salt, and exhibit significantly
changed TAOxC and levels of MDA, SOD, and GSH
[16, 26]. The in vitro liver damage caused by CCl4 has
been hypothesized to be caused by two different mecha-
nisms, depending on the concentration used and the
exposure time: a direct solvent effect of the molecule it-
self or an indirect effect through the generation of free
radicals and subsequent lipid peroxidation [27].
Berger et al. studied the induction of cell membrane
damage in isolated rat hepatocytes during the first 10–
30 min of exposure to 20% CCl4 in ethanol by quantify-
ing the MDA level as a marker of lipid peroxidation
[28]. They postulated that these changes were caused by
the direct action of the solvent, which affected the cell
membrane, and that such changes are not preventable
by antioxidant treatment within the initial 30 min of ex-
posure. In the current study, CCl4 did not cause toxic ef-
fects or increase MDA level within 30 min, but effects
were seen at 60 min; this observation seems to exclude
any direct solvent effect. Holden et al. reported that the
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toxic effect of CCl4 at a concentration of 0.18% in HepG2
cells, as measured by release of LDH into the culture
medium, increased significantly beginning at 1.5 h and
LDH increased the release by up to 50% [26]. In our study,
compared with control cells, HepG2 cells exposed to CCl4
exhibited a similar LDH response at 1.5 h.
One study found significant participation of lipid per-
oxidation in the toxic effects via formation of free radi-
cals and loss of viability in these cells after exposure to
0.5% CCl4 for 2 h [16]. We found that, compared with
control cells, HepG2 cells exposed to CCl4 showed
significantly reduced viability, reduced TAOxC and GSH
and SOD levels, and increased AST, LDH, and MDA
activities at 1.5 h. ALT activity did not change signifi-
cantly, although this lack of change may relate to the
timing of exposure to the toxic agent because previ-
ous studies have shown time-dependent increments in
ALT activity [6, 7].
Oxidative stress also plays a major role in APAP toxicity.
Oxidative stress occurs when the generation of reactive
oxygen species overwhelms the ability to detoxify the re-
active intermediates or exceeds the capacity to repair the
Fig. 1 Time-dependent changes in HepG2 cells. a Cell viability, b AST, c LDH, d ALT, e TAOxC, f SOD, g GSH, and h MDA levels after exposure to 20,
30, or 40 mM CCl4. Control: DMSO (0.05% v/v) in supplemented DMEMA; CCl4 20 mM: 1.92 μL of CCl4/DMSO (0.05% v/v) in supplemented DMEMA;
CCl4 30 mM: 2.88 μL of CCl4/DMSO (0.05% v/v) in supplemented DMEMA; CCl4 40 mM: 3.84 μL of CCl4/DMSO (0.05% v/v) in supplemented DMEMA.
Values are the mean ± SD of three independent experiments performed in triplicate. aP <0.05 vs C; bP <0.01 vs C
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resulting damage [29]. It has been reported that high
APAP levels cause injury and reduce viability by up to
80% at 24 h [30]. In our study, HepG2 cells exposed to
APAP showed similar results, and cell death was greatest
after the longest exposure time (72 h). In other studies,
HepG2 cells were exposed to serial concentrations of
APAP for 24 and 72 h, and LDH release increased with a
dose of 10 mM [31]. By contrast, in our study, increases in
AST, ALT, and LDH release were evident only during the
first 12 h. However, the decreases in the TAOxC and SOD
and GSH levels, and the increase in MDA level were time
dependent throughout the observation period. HepG2
cells are killed by APAP [32, 33], but the mechanism caus-
ing death differs between HepG2 cells and cells that form
a reactive metabolite, which causes apoptosis. For this rea-
son, GSH depletion does not occur in HepG2 cells at
12 h [34], and our finding that GSH started to decrease
only after 12 h is consistent with this observation. Be-
cause of the variability of the results obtained with
APAP, the best inducer of cell injury in our study was
CCl4 after 1.5 h incubation and at a concentration of
40 mM. Experimental results using various mediators
Fig. 2 Changes after exposure to 2, 4, or 8 mM APAP in HepG2 cells. a Cell viability, b AST, c LDH, d ALT, e TAOxC, f SOD, g GSH, and h MDA
levels. Control: supplemented DMEMA; APAP 2 mM: 2 μL in supplemented DMEMA; APAP 4 mM: 4 μL in supplemented DMEMA; APAP 8 mM:
8 μL in supplemented DMEMA. Values are the mean ± SD of three independent experiments performed in triplicate. aP <0.05 vs C; bP <.01 vs C
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of oxidative stress confirm the involvement of free radi-
cals acting through lipid peroxidation, as reported for
this toxic agent [6, 7, 16, 26, 28].
The hepatoprotective effects of S. marianum are due
mainly to its antioxidant content. The DPPH assay is
based on the reduction of the stable DPPH radical to a
yellow diphenyl picryl hydrazine, which is a common
spectrophotometric method for measuring the antioxi-
dant capacity of compounds. Thus, the ability of SLM,
SLB, and SLP to quench this radical is a measure of an-
tioxidative activity. In this assay, the antioxidative activ-
ity was greater for SLB than for SLM, and for SLM
than for SLP. The lower activity of SLP might relate to
interactions between the different substances in the
compound evaluated (Medix). The antioxidative activ-
ities of SLB and SLM that we observed are in agree-
ment with previous research, which has reported strong
DPPH free radical-scavenging activity for these com-
pounds [35, 36].
Before evaluating the hepatoprotective activity of the
various concentrations of SLM, SLB, and SLP, it was
necessary to demonstrate that they are nontoxic. These
compounds were not cytotoxic according to the definition
of toxicity as a >60% decrease in cell viability compared
with untreated cells, AST level <50 IU/L, ALT level
<30 IU/L, TAOxC <2 mM or MDA, SOD, or GSH level
Fig. 3 Effects of silybinin, silymarin, and silyphos at concentrations of 10, 100, and 150 μg/mL for 12 h in HepG2 cells. The values are the mean ± SD.
aP <0.05 vs C; bP <0.01 vs C
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less than that of the control [25]. This finding is in agree-
ment with those of previous studies [35–37].
We evaluated the hepatoprotective activities of SLM,
SLB, and SLP against CCl4-induced liver damage at a
dose of 40 mM for 1.5 h. In other in vivo models, S.
marianum was reported to increase GSH level and to
decrease MDA level, and SLB was shown to be the
major biologically active component of SLM [12, 38, 39].
We found that pretreatment with SLB at the highest
doses prevented the biochemical alterations indicative of
damage induced by CCl4, although SLM did not have
significant effects on cell viability at any of the doses
studied.
It is important to mention that one way of indirectly
assessing the damage to HepG2 cells caused by free radicals
is by measuring the activities of intracellular enzymes (e.g.,
GSH, SOD) and TBARS, and the viability of cultured cells
using the MTT assay. These measurements are useful for
assessing the in vitro antioxidative actions of the hepato-
protective plant extracts [25, 40–43]. However, it has been
proposed that other isolated active compounds in addition
to those mentioned above should be included when
Fig. 4 Hepatoprotective effects of silybinin, silymarin, and silyphos against damage induced by 40 mM CCl4 for 1.5 h in HepG2 cells. The values
are the mean ± SD. aP <0.05 vs CCl4;
bP <0.01 vs CCl4
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evaluating the intracellular formation of reactive oxygen
species, mitochondrial membrane potential, and changes in
cell nuclei morphology in in vitro models. However, the use
of all of these compounds may not be practical for routine
testing because of the high cost of their inclusion in the
monitoring of the hepatoprotective activities of all plant
extracts [44–47].
Conclusion
The findings from this study show that CCl4 was a better
injury inducer than APAP when used with 1.5 h incuba-
tion and at a concentration of 40 mM. SLB at a dose of
150 μg/mL was an adequate positive control for studying
hepatoprotection. AST, LDH, and MDA were good
markers of liver damage in HepG2 cells.
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